Entering the NASH Race: Tips for Early Clinical Development
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease that affects over 17 million Americans and this number is growing. NASH can lead to cirrhosis, end-stage liver disease, liver transplant and even hepatocellular carcinoma. Therefore, the need for treatment for this … Continue reading
Oct 2018The Next Frontier of Pharmacology: Micro Drug Delivery
Injectable medication can be burdensome for the patient, causing pain and discomfort, and can contribute to compliance issues especially when chronic treatment is required. A promising and emerging area in pharmacology that may alleviate these obstacles is transdermal microneedle drug … Continue reading
Jul 2018Know Your Numbers Campaign
Know Your Numbers Campaign At Celerion, our community outreach does not only serve to inform the public about who we are and medical research opportunities, but we also use this time to give back to our community. In April 2016, … Continue reading
Apr 2018Prediabetes, the New Normal in Early Clinical Research
Prediabetes, the New Normal in Early Clinical Research There is a growing shift in inclusion criteria from healthy normal subjects to patient groups in early drug development. For programs with a chronic metabolic disease investigational product, prediabetes subject enrollment in … Continue reading
Nov 2017Supporting the Next Major Health Epidemic
Supporting the Next Major Health Epidemic Non-alcoholic fatty liver disease (NAFLD)/Non-alcoholic steatohepatitis (NASH) is viewed as the next major health epidemic and with no current anti-NASH medication on the market to treat this chronic disease; it is expected to place … Continue reading
Aug 2016